当前位置: 首页 > 期刊 > 《中国药房》 > 202022
编号:13790585
影响表观遗传学的药物在炎症性肠病治疗中的研究进展(8)
http://www.100md.com 2020年11月15日 《中国药房》 202022
     [60] GUSLANDI M. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis[J]. J Clin Gastroenterol,2010. DOI:10.1097/MCG.ob013e3181cb4233.

    [61] MALDONADO-GOMEZ MX,MARTINEZ I,BOTTACINI F,et al. Stable engraftment of bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome[J]. Cell Host Microbe,2016,20(4):515-526.

    [62] KHORUTS A,DICKSVED J,JANSSON JK,et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea[J]. J Clin Gastroenterol,2010,44(5):354- 360.

    [63] DUVALLET C,ZELLMER C,PANCHAL P,et al. Framework for rational donor selection in fecal microbiota transplant clinical trials[J]. PLoS One,2019. DOI:10.1371/journal.pone.0222881.

    [64] WANG ZK,YANG YS,CHEN Y,et al. Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease[J]. World J Gastroenterol,2014,20(40):14805-14820.

    (收稿日期:2020-07-07 修回日期:2020-10-22)

    (編辑:孙 冰), 百拇医药(伍建中 刘衡 武琦梅 杨旭芹 张成桂 巫秀美 张瑱 葛建)
上一页1 2 3 4 5 6 7 8